The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the establishment of its scientific advisory board to provide strategic guidance and evaluation of its research portfolio and programs. The 11-person advisory board, which brings together global leaders in immunotherapy and immunobiology, will hold its inaugural meeting today.
The advisory board will be co-chaired by Robert Schreiber...

The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center and Empyrean Medical Systems, Inc. today announced an exclusive license and joint development agreement to advance novel technologies and products in the fields of radiation oncology and cancer therapeutics.
This agreement brings together the complementary research and development expertise of both institutions to advance innovative intellectual property from MD Anderson to...

The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode...
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report...
Cancer cells produce small amounts of their own form of collagen, creating a unique extracellular matrix that affects the tumor microbiome...
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (...
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased...